Showing results (941-950 of 1,211) with videos related to

Sort By:
Pageof 122
JACC. Heart Failure|February 5, 2026
Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HFMisato Chimura, Alasdair D Henderson, Pardeep S Jhund, et al.
Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.
The Journal of Infection|September 20, 2024
Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: A post hoc analysis of the DANFLU-1 randomized clinical trialJacob Christensen, Niklas Dyrby Johansen, Kira Hyldekær Janstrup, et al.
Circulation. Heart Failure|May 9, 2026
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid CardiomyopathyAhmad Masri, Francesco Cappelli, Margot K Davis, et al.
Circulation. Heart Failure|November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF TrialJawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Lancet (London, England)|December 5, 2016
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trialJohn R Teerlink, G Michael Felker, John J V McMurray, et al.
Circulation|October 13, 2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER TrialJohn W Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
European Journal of Heart Failure|February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trialJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
European Journal of Heart Failure|December 15, 2024
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HFXiaowen Wang, Orly Vardeny, Brian Claggett, et al.
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
Pageof 122